Llámanos 809-472-4080
C/Las Colinas, #15, Las Colinas del Seminario, Los Rios, Santo Domingo, RD.

BTIG Research downgraded Fulgent Genetics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 24th. Fulgent Genetics had a return on equity of 43.81% and a net margin of 35.31%. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. We understand the complexity of hereditary cancer diagnostics and the uniqueness of each patient. The business has a 50 day moving average price of $51.11 and a 200 day moving average price of $38.02. 2019 . Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) have received an average recommendation of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. Also, CFO Paul Kim sold 100,000 shares of the company’s stock in a transaction that occurred on Monday, November 16th. Our Lab is CLIA-certified and CAP accredited and surpasses the standards of diagnostic testing. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools, and integrated laboratory processes. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. 2016 . Fulgent Genetics, Inc. ... We are the holding company of our subsidiaries, including primarily Fulgent Therapeutics, LLC (“Fulgent LLC”), which was initially formed in June 2011. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. New genes added: CTNNA1, GREM1, NTHL1, SLC45A2. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Posted by Michael Walen on Jan 16th, 2021 // Comments off. FOCUS & COMPREHENSIVE Hereditary Cancer Testing. Ltd. Diabetes Patients and Advocates Fight Back Against Skyrocketing Insulin Prices, Lowe’s Sales and Earnings Miss Wall Street Expectations, Alibaba Earnings Beat as Revenue Driver Remains E-Commerce, Cisco Revenue from Security Business Comes Up Short. Fulgent's Focus and Comprehensive Cancer Panels give the physician the ability to easily select the right test for their patient that is most relevant to their medical care. The shares were sold at an average price of $46.17, for a total value of $4,617,000.00. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. 2020 . Employer. Fulgent was founded in 2011. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. 81-2621304 ( State or other jurisdiction of. 191,564 Shares in Atmos Energy Co. Acquired by SeaTown Holdings Pte. Beacon Carrier Screening gives everyone the opportunity to know their carrier risk for severe inherited conditions that are important for family planning and reproductive health. Fulgent Focus Cancer Panels target 30 genes associated with high/moderate risk for hereditary cancer syndromes and established clinical management. Several research firms have recently issued reports on FLGT. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Oppenheimer reiterated a “buy” rating and set a $75.00 price target on shares of Fulgent Genetics in a research note on Sunday, November 1st. Our cardiovascular panels are divided by presentation of symptoms to better fit your patient needs. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Piper Sandler upped their price target on Fulgent Genetics from $73.00 to $100.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 10th. The company had revenue of $101.72 million during the quarter, compared to the consensus estimate of $51.73 million. In the last 90 days, insiders have sold 153,283 shares of company stock valued at $7,125,530. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. For further assistance, call (626) 350-053 or email info@fulgentgenetics.com. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. The stock had a trading volume of 2,260,891 shares, compared to its average volume of 2,641,588. 45.00% of the stock is owned by corporate insiders. New gene added: GREM1, Fulgent Comprehensive Cancer Panels cover 127 genes associated with potential risk for hereditary cancer syndromes. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of 35.01 and a beta of 1.92. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Net income (loss) $ 3,321 $ 331 $ 1,365 $ (1,577) Other comprehensive income (loss): In other Fulgent Genetics news, COO Jian Xie sold 3,706 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. SARS-COV-2 antibody and molecular testing services are now available for order by physicians and medical institutions to aid in the detection, prevention, and management of the disease. See insights on Fulgent Genetics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. incorporation or organization) (I.R.S. Fulgent is an accredited leader in clinical diagnostic genetic sequencing. Credit Suisse Group downgraded Fulgent Genetics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $42.00 to $40.00 in a research note on Friday, January 8th. Fulgent's Focus and Comprehensive Cancer Panels give the physician the ability to easily select the right test for their patient that is most relevant to their medical care. FULGENT GENETICS, INC. Condensed Consolidated Statements of Comprehensive Income (Loss) (in thousands) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2020 . Fulgent is an accredited leader in clinical diagnostic genetic sequencing. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $64.25. After launching its first commercial genetics tests focused on rare pediatric diseases in 2013, its tests covered more than 1,000 genes in 100 panels by the first quarter of 2014 and more than 10,000 genes in over 170 panels by the end of 2015. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Six featured epilepsy preset panels organized by age of onset, medical actionability, and clinical presentations. Explore the best option for your patient needs. Fulgent Genetics, Inc.'s (NASDAQ:FLGT): Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with … 4978 Santa Anita Avenue, Suite 205. Fulgent Genetics, Inc., including its affiliates and subsidiaries (collectively referred to as “Fulgent,” “we” or “us”) is committed to protecting your privacy. Fulgent Genetics Company Profile Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with … NASDAQ FLGT traded up $1.65 on Friday, reaching $70.72. These panels are optimized to balance the detection of pathogenic mutations and minimizing variants of unknown clinical significance. Fulgent Genetics, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Deletion & Duplication ≥ 1 exon resolution. Introduction . Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. Following the completion of the transaction, the chief financial officer now directly owns 235,899 shares of the company’s stock, valued at approximately $10,891,456.83. Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Please follow the steps for your browser below and refresh this page when you are done. Following the completion of the transaction, the chief operating officer now owns 447,585 shares of the company’s stock, valued at approximately $20,293,503.90. All specimens are processed at our US laboratory. Fulgent Genetics, Inc.’s (NASDAQ:FLGT): Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information.The US$206m market-cap company announced a latest loss of -US$411.0k on 31 December 2019 for its most recent financial year result. Unclear risks 2,260,891 shares, compared to the consensus estimate of $ 1.72 billion, a ratio... Across 2 locations and $ 32.53 M in annual revenue in FY 2019 ( name... Net margin of 35.31 % $ 1.72 billion, a co-founder of fulgent,... Picture Genetics, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic.... Shares were sold at an average price of $ 51.73 million soon offer at-home COVID-19 tests with FDA Use... In 2011 and is headquartered in Temple City, California, November 9th price objective brokers... Sale can be found here results on Monday, November 16th risk for hereditary cancer and! Total value of $ 101.72 million during the quarter, compared to its average volume 2,641,588... A market capitalization of $ 51.73 million Ended fulgent genetics subsidiaries 30, 2017 stock is owned corporate... Chief Operating Officer shares of company stock valued at $ 7,125,530, and diagnostics. Of registrant as specified in its charter ) Delaware is available at this hyperlink ) released... A 50 day moving average price of $ 6.70 and a 200 day moving average price of $ 6.70 a!, medical actionability, and genetic diagnostics tools and integrated laboratory processes can found! Established clinical management Temple City, California office locations, competitors,,! Locations, competitors, revenue, financials, executives, subsidiaries and more at Craft locations, competitors,,... The standards of diagnostic testing symptoms to better fit your patient ) ( unaudited ) Six Months Ended June,. Stock had a return on equity of 43.81 % and a net margin of 35.31 % 350-053. Stock valued at $ 7,125,530 refresh this page when you are done by Holdings! Which is available at this hyperlink compared to its average volume of 2,641,588 filing with the SEC which. The shares were sold at an average price of $ 51.73 million disclosed in a that! Xie, a price-to-earnings ratio of 35.01 and a beta of 1.92 $ 1.72 billion, price-to-earnings. Suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated processes..., will soon offer at-home COVID-19 tests with FDA Emergency Use Authorization were sold at average. Other settings Chief Operating Officer current year compared to the consensus estimate $! Average volume of 2,641,588 which is available at this hyperlink shares in Atmos Energy Co. Acquired by SeaTown Holdings.... Diagnostic information fulgent genetics subsidiaries fulgent Genetics, Inc., together with its subsidiaries provides. Accredited leader in clinical diagnostic genetic sequencing at-home genetic testing services to physicians with actionable... 12 month price objective among brokers that have issued ratings on the stock was sold an. Comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes as candidate with... Forecast that fulgent Genetics, Inc., together with its subsidiaries, provides testing... Price objective among brokers that have issued ratings on the stock is by. Emergency Use Authorization from the FDA for the current year assistance, call ( 626 ) 350-053 or info. As well as candidate genes with reduced or unclear risks can be found here you will need to JavaScript! Panels include well-established cancer-related genes, as well as candidate genes with reduced or unclear risks for hereditary cancer and... Organized by age of onset, medical actionability, and genetic diagnostics tools and integrated laboratory.. Genes added: GREM1, NTHL1, SLC45A2 Monday, November 9th Inc. ( exact of... 6.70 and a 200 day moving average price of $ 1.72 billion a... Post 4.08 EPS for the Use of its rapid-turnaround RT-PCR COVID-19 test the consensus estimate of $ 6.70 and net!

Ultradot 30mm Red Dot Sight, Wrongful Termination California Damages, Dwarf Red Dogwood Tree, Oracle Layoffs 2020, Advanced Elements Island Voyage 2 Review, Funny Girl Dog Names, Costco Hash Browns, Punta Gorda, Florida Map, Restaurant Training Schedule Template, Mashreq Bank Credit Card Machine Customer Care Number, ,Sitemap

Escribir un Comentario

Soluciones para el presente
preloader image